Oxygen: Putting a Human Face on Science

Oxygen--the 'science-in-fiction' play written by chemists Carl Djerassi and Roald Hoffmann--will permeate the Royal Institution as it debuts in London Oct. 27. With the premiere at the San Diego Repertory Theater in California and publication of the play (Wiley-VCH) last Spring, Djerassi, also known as 'Father of The Pill,' and Nobel laureate Hoffmann garnered kudos from an A-list of science 'critics' and respectable notice in theater circles. From Nobel laureates Harold Varmus and Murray Gell-M

Written byA. J. S. Rayl
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The two-act drama is based on the premise that the Nobel Committee has decided in this, its centenary year to give the first "retro-Nobel" to the discoverer of oxygen. Three chemists, the committee quickly determines, lay a claim to that discovery:

Through the trials and tribulations of the three contenders and the members of the Nobel Committee, Djerassi and Hoffmann take the audience 'backstage' for an inside look at the politics and passions in science then and now. The play opens in Stockholm, Sweden, 1777 (the year oxygen was discovered) and, with a very intentional nod to women, introduces Lavoisier, Priestly, and Scheele vicariously through their wives. Scene Two fast-forwards to 2001 where the Nobel Committee--led by a woman--sets about the task of selecting the recipient(s). From there, the action shifts from one century to the other, as the actors, who play dual roles, make seamless costume and character changes.

...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies